← All trials
NCT04350320
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2020
- Primary completion
- Oct 20, 2020
- Completion date
- Nov 20, 2020
- First posted
- Apr 17, 2020
- Last posted
- Apr 17, 2020
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaLead sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.